Affordable Inhalers and Nebulizers Act of 2025

Hozzl · 2025-10-07T15:58:44Z

Explore the details of House Bill 5278 Affordable Inhalers and Nebulizers Act of 2025 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/7/2025, 3:58 PM

Summary of Bill HR 5278

This bill, designated as H.R. 5278 in the 119th Congress and introduced on September 10, 2025, aims to amend various health and tax laws to decrease patient cost-sharing specifically for prescription drug inhaler products utilized in managing breathing disorders like asthma and chronic obstructive pulmonary disease. The bill includes provisions focused on reducing the financial burden on patients seeking treatment for these conditions.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 5278

Bill HR 5278 is currently in the status of Bill Introduced since September 10, 2025. Bill HR 5278 was introduced during Congress 119 and was introduced to the House on September 10, 2025. Bill HR 5278's most recent activity was Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. as of September 10, 2025

Bipartisan Support of Bill HR 5278

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 5278

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 5278

To amend title XXVII of the Public Health Service Act, the Internal Revenue Code of 1986, and the Employee Retirement Income Security Act of 1974 to reduce patient cost-sharing for prescription drug inhaler products used to treat breathing disorders such as asthma and chronic obstructive pulmonary disease, and for other purposes.